RocRock Biotechnology
Latest round
- Angel
Last raised
- Oct 2022
Total raised
- Undisclosed
Investors
- 2
About RocRock Biotechnology
, Ltd, RocRock Bio operates as a provider of engineered macrophage technology, focusing on the development and clinical application of macrophage drugs for the treatment of solid tumors. The branches have been set up in Shenzhen and Berlin. The founder, Dr. Xiushan Yin, is a senior researcher at Karolinska Medical School. Its core team members were from scientific research institutions such as the European Molecular Biology Laboratory and the German National Center for Molecular Medicine. The company has completed the declaration and approval of nearly 40 patents and established partnerships with SYPM, and Peking Union Medical College Hospital. RocRock Bio's core platforms include the "24H-CAR" technology platform for chimeric antigen receptor macrophage (CAR-M) preparation, the "ADM-CAR" enhanced synthesis platform based on iterative screening of macrophage activation structural domains, the "Del-M" macromolecule delivery platform using macrophages as carriers, and the "M-DB" subtype database and target database platform. The platforms and drugs can be used to treat breast cancer, lung cancer, liver cancer, and other rare diseases. The company generates revenue by developing drugs targeting solid tumor cells.
Who invested in RocRock Biotechnology
2 investors across 1 round
See all investors in RocRock Biotechnology
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Angel
Oct 17, 2022
Amount
Undisclosed
Investors
Questions about RocRock Biotechnology
Who invested in RocRock Biotechnology?
RocRock Biotechnology has 2 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has RocRock Biotechnology raised?
RocRock Biotechnology has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did RocRock Biotechnology last raise money?
RocRock Biotechnology's most recent round on record is a Angel, in Oct 2022.
What does RocRock Biotechnology do?
, Ltd, RocRock Bio operates as a provider of engineered macrophage technology, focusing on the development and clinical application of macrophage drugs for the treatment of solid tumors.
Where is RocRock Biotechnology headquartered?
RocRock Biotechnology is headquartered in Suzhou, China.
Which VCs invest in companies like RocRock Biotechnology?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Peak XV Partners, MPCi and Luminous Ventures back biotechnology companies at RocRock Biotechnology's stage. Their profiles are linked below.
VCs backing biotechnology startups at Angel
Raising like RocRock Biotechnology? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.